دورية أكاديمية
أعرض في EDS

Potential Advances of Adjunctive Hyperbaric Oxygen Therapy in Infective Endocarditis.

التفاصيل البيبلوغرافية
العنوان: Potential Advances of Adjunctive Hyperbaric Oxygen Therapy in Infective Endocarditis.
المؤلفون: Lerche CJ; Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Virus and Microbiology Special Diagnostics, Statens Serum Institut, Copenhagen, Denmark., Schwartz F; Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Pries-Heje MM; Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Fosbøl EL; Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Iversen K; Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark.; Department of Emergency Medicine, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark., Jensen PØ; Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Immunology and Microbiology, Costerton Biofilm Center, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Høiby N; Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Immunology and Microbiology, Costerton Biofilm Center, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Hyldegaard O; Department of Anaesthesia, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Bundgaard H; Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Moser C; Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Immunology and Microbiology, Costerton Biofilm Center, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
المصدر: Frontiers in cellular and infection microbiology [Front Cell Infect Microbiol] 2022 Feb 03; Vol. 12, pp. 805964. Date of Electronic Publication: 2022 Feb 03 (Print Publication: 2022).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Review
اللغة: English
بيانات الدورية: Publisher: Frontiers Media SA Country of Publication: Switzerland NLM ID: 101585359 Publication Model: eCollection Cited Medium: Internet ISSN: 2235-2988 (Electronic) Linking ISSN: 22352988 NLM ISO Abbreviation: Front Cell Infect Microbiol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Lausanne : Frontiers Media SA
مواضيع طبية MeSH: Endocarditis, Bacterial* , Hyperbaric Oxygenation*, Animals ; Anti-Bacterial Agents/therapeutic use ; Combined Modality Therapy ; Humans ; Treatment Outcome
مستخلص: Patients with infective endocarditis (IE) form a heterogeneous group by age, co-morbidities and severity ranging from stable patients to patients with life-threatening complications with need for intensive care. A large proportion need surgical intervention. In-hospital mortality is 15-20%. The concept of using hyperbaric oxygen therapy (HBOT) in other severe bacterial infections has been used for many decades supported by various preclinical and clinical studies. However, the availability and capacity of HBOT may be limited for clinical practice and we still lack well-designed studies documenting clinical efficacy. In the present review we highlight the potential beneficial aspects of adjunctive HBOT in patients with IE. Based on the pathogenesis and pathophysiological conditions of IE, we here summarize some of the important mechanisms and effects by HBOT in relation to infection and inflammation in general. In details, we elaborate on the aspects and impact of HBOT in relation to the host response, tissue hypoxia, biofilm, antibiotics and pathogens. Two preclinical (animal) studies have shown beneficial effect of HBOT in IE, but so far, no clinical study has evaluated the feasibility of HBOT in IE. New therapeutic options in IE are much needed and adjunctive HBOT might be a therapeutic option in certain IE patients to decrease morbidity and mortality and improve the long-term outcome of this severe disease.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2022 Lerche, Schwartz, Pries-Heje, Fosbøl, Iversen, Jensen, Høiby, Hyldegaard, Bundgaard and Moser.)
References: Circulation. 2015 Feb 10;131(6):571-81. (PMID: 25527699)
Immunol Lett. 2002 Sep 2;83(2):125-31. (PMID: 12067761)
Plast Reconstr Surg. 1993 May;91(6):1110-23. (PMID: 8479978)
Inflammation. 2018 Dec;41(6):2003-2011. (PMID: 30073566)
J Infect. 2007 Oct;55(4):369-73. (PMID: 17675245)
Eur Surg Res. 1999;31(2):147-54. (PMID: 10213853)
Lancet. 2004 Jan 10;363(9403):139-49. (PMID: 14726169)
N Engl J Med. 2019 Apr 4;380(14):1373-1374. (PMID: 30883059)
Arterioscler Thromb Vasc Biol. 2018 Aug;38(8):1901-1912. (PMID: 29976772)
Nature. 2002 Mar 21;416(6878):291-7. (PMID: 11907569)
Circ Res. 1995 Sep;77(3):638-43. (PMID: 7641334)
Brain Res. 1995 Nov 6;698(1-2):79-85. (PMID: 8581506)
Infect Immun. 1974 Feb;9(2):337-41. (PMID: 4361295)
Front Cell Infect Microbiol. 2014 Jul 28;4:99. (PMID: 25120957)
Undersea Hyperb Med. 2014 May-Jun;41(3):253-7. (PMID: 24984321)
J Clin Invest. 1988 Feb;81(2):624-9. (PMID: 3339135)
Crit Care Med. 2003 Apr;31(4):1048-52. (PMID: 12682471)
Thromb Haemost. 2019 May;119(5):786-796. (PMID: 30731490)
J Infect Dis. 1986 Apr;153(4):676-81. (PMID: 3081661)
J Infect Dis. 1993 Oct;168(4):910-4. (PMID: 8376837)
Microvasc Res. 2019 Jul;124:6-18. (PMID: 30742844)
FEMS Immunol Med Microbiol. 2010 Aug;59(3):292-305. (PMID: 20579098)
Clin Biochem. 2005 Aug;38(8):722-6. (PMID: 15946662)
Br J Exp Pathol. 1972 Feb;53(1):44-9. (PMID: 5014243)
Heart. 2021 Oct 5;:. (PMID: 34611042)
Anaerobe. 2017 Oct;47:33-38. (PMID: 28389412)
Ann Surg. 1975 Jan;181(1):35-9. (PMID: 804296)
J Appl Physiol (1985). 2009 Feb;106(2):711-28. (PMID: 19023021)
Infect Immun. 1992 Mar;60(3):1202-9. (PMID: 1541535)
J Clin Invest. 2016 May 2;126(5):1612-20. (PMID: 27135878)
Int J Antimicrob Agents. 2016 Feb;47(2):163-7. (PMID: 26774522)
J Investig Med. 2021 Oct;69(7):1330-1338. (PMID: 34006573)
Diving Hyperb Med. 2017 Mar;47(1):24-32. (PMID: 28357821)
PLoS One. 2019 Apr 19;14(4):e0215333. (PMID: 31002679)
Br J Exp Pathol. 1972 Feb;53(1):50-3. (PMID: 4111329)
Crit Care Med. 2004 Aug;32(8):1722-9. (PMID: 15286550)
Proc Natl Acad Sci U S A. 1971 May;68(5):1024-7. (PMID: 4995818)
Int J Biochem Cell Biol. 2007;39(1):44-84. (PMID: 16978905)
Free Radic Biol Med. 2008 Mar 15;44(6):921-37. (PMID: 18155672)
Adv Wound Care (New Rochelle). 2017 Jun 1;6(6):210-224. (PMID: 28616361)
Clin Exp Pharmacol Physiol. 2011 Oct;38(10):675-82. (PMID: 21711378)
Int J Environ Res Public Health. 2021 Sep 16;18(18):. (PMID: 34574676)
Front Immunol. 2015 Feb 26;6:82. (PMID: 25767472)
J Exp Med. 1988 Aug 1;168(2):527-42. (PMID: 3411289)
Neurol Res. 2007 Mar;29(2):127-31. (PMID: 17439696)
Antibiotics (Basel). 2021 Apr 30;10(5):. (PMID: 33946290)
JCI Insight. 2016 Jul 7;1(10):e87882. (PMID: 27699220)
Eur Heart J. 2019 Oct 14;40(39):3248-3259. (PMID: 30945735)
J Appl Physiol (1985). 2021 Mar 1;130(3):729-736. (PMID: 33444122)
Undersea Hyperb Med. 2016 Mar-Apr;43(2):113-22. (PMID: 27265988)
Front Cell Dev Biol. 2021 Jun 18;9:643335. (PMID: 34222225)
J Thromb Haemost. 2017 May;15(5):1009-1019. (PMID: 28182324)
Crit Care Med. 1990 Sep;18(9):974-9. (PMID: 2394122)
APMIS. 2017 Apr;125(4):320-338. (PMID: 28407429)
Surg Forum. 1976;27(62):18-20. (PMID: 1019847)
Undersea Hyperb Med. 2016 Jan-Feb;43(1):21-8. (PMID: 27000010)
Biofilm. 2019 Nov 04;1:100008. (PMID: 33447795)
Free Radic Res. 2008 Aug;42(8):689-706. (PMID: 18671159)
J Wound Care. 2017 Jan 2;26(1):20-25. (PMID: 28103163)
Undersea Hyperb Med. 2003 Winter;30(4):305-11. (PMID: 14756233)
Appl Microbiol. 1967 Sep;15(5):1020-4. (PMID: 6077408)
Liver. 1998 Apr;18(2):110-6. (PMID: 9588769)
Eur Heart J. 2019 Oct 14;40(39):3222-3232. (PMID: 31504413)
BMC Pulm Med. 2019 Aug 13;19(1):148. (PMID: 31409407)
APMIS. 2021 Sep;129(9):566-573. (PMID: 34120378)
Antimicrob Agents Chemother. 2017 Oct 24;61(11):. (PMID: 28874373)
Ann Chir Gynaecol. 2000;89 Suppl 214:7-36. (PMID: 11288993)
J Bacteriol. 2003 May;185(10):3214-7. (PMID: 12730182)
N Engl J Med. 2019 Jan 31;380(5):415-424. (PMID: 30152252)
Circulation. 2013 Jul 2;128(1):50-9. (PMID: 23720451)
Proc Natl Acad Sci U S A. 2009 May 12;106(19):7786-91. (PMID: 19416890)
J Biol Chem. 1979 May 25;254(10):4022-6. (PMID: 312289)
Infect Immun. 1997 Nov;65(11):4652-60. (PMID: 9353046)
Nat Rev Cardiol. 2014 Jan;11(1):35-50. (PMID: 24247105)
Eur J Clin Microbiol Infect Dis. 2015 Dec;34(12):2349-57. (PMID: 26440039)
J Infect Dis. 1980 Dec;142(6):915-22. (PMID: 7462700)
Circulation. 1993 Oct;88(4 Pt 1):1931-6. (PMID: 8403338)
Nat Rev Microbiol. 2006 Apr;4(4):295-305. (PMID: 16541137)
Thromb Res. 1999 Nov 15;96(4):309-15. (PMID: 10593434)
Antimicrob Agents Chemother. 2009 Apr;53(4):1443-9. (PMID: 19188397)
Immunol Lett. 1985;11(3-4):159-63. (PMID: 3910565)
Eur J Clin Microbiol Infect Dis. 2012 Oct;31(10):2567-74. (PMID: 22431272)
Infect Immun. 2005 Jun;73(6):3261-70. (PMID: 15908350)
BMC Cardiovasc Disord. 2017 Dec 12;17(1):291. (PMID: 29233094)
Plast Reconstr Surg. 2011 Jan;127 Suppl 1:131S-141S. (PMID: 21200283)
Appl Microbiol. 1975 Nov;30(5):781-5. (PMID: 173238)
Nat Med. 2003 Jun;9(6):669-76. (PMID: 12778165)
J Leukoc Biol. 2004 Oct;76(4):760-81. (PMID: 15240752)
Br J Exp Pathol. 1973 Apr;54(2):142-51. (PMID: 4700697)
Antimicrob Agents Chemother. 1978 Sep;14(3):336-43. (PMID: 251069)
Int J Cardiol. 2021 Mar 1;326:145-152. (PMID: 33069786)
PLoS One. 2018 Jun 14;13(6):e0198909. (PMID: 29902223)
Antimicrob Agents Chemother. 1993 Nov;37(11):2474-7. (PMID: 8285637)
Thromb Haemost. 2001 Jul;86(1):189-97. (PMID: 11487007)
J Surg Res. 2016 May 1;202(1):66-70. (PMID: 27083949)
QJM. 2004 Jul;97(7):385-95. (PMID: 15208426)
Infect Immun. 1974 Sep;10(3):546-52. (PMID: 4214774)
Medicine (Baltimore). 2012 May;91(3):152-164. (PMID: 22543628)
Int J Antimicrob Agents. 2017 Sep;50(3):406-412. (PMID: 28669832)
Front Cardiovasc Med. 2019 Jun 20;6:85. (PMID: 31281822)
PLoS One. 2016 Aug 16;11(8):e0161343. (PMID: 27529549)
Intensive Care Med. 2004 Nov;30(11):2046-52. (PMID: 15372147)
mBio. 2015 Aug 25;6(4):. (PMID: 26307164)
Arch Biochem Biophys. 2002 Jan 15;397(2):342-4. (PMID: 11795892)
J Clin Invest. 1996 Jan 15;97(2):493-500. (PMID: 8567972)
Free Radic Res. 1995 Aug;23(2):91-101. (PMID: 7581815)
Toxicol Appl Pharmacol. 1990 Sep 1;105(2):340-4. (PMID: 2219124)
Am J Med. 2005 Jul;118(7):759-66. (PMID: 15989910)
Life Sci. 2013 Jul 30;93(2-3):125-31. (PMID: 23770209)
Scand J Infect Dis. 1995;27(6):569-73. (PMID: 8685635)
J Pediatr Surg. 1995 Jun;30(6):786-90. (PMID: 7666307)
Antimicrob Agents Chemother. 2008 May;52(5):1829-33. (PMID: 18332172)
Annu Rev Physiol. 1986;48:703-19. (PMID: 3010832)
Shock. 2011 Jul;36(1):12-7. (PMID: 21372753)
J Immunol. 2011 Jan 1;186(1):453-463. (PMID: 21135168)
J Pathol. 1975 Feb;115(2):81-9. (PMID: 1151519)
Open Heart. 2021 Oct;8(2):. (PMID: 34670832)
Platelets. 2015;26(4):286-92. (PMID: 25806786)
Am J Physiol Heart Circ Physiol. 2006 Apr;290(4):H1378-86. (PMID: 16299259)
J Pharmacol Exp Ther. 1996 Mar;276(3):929-33. (PMID: 8786572)
Antioxid Redox Signal. 2009 Nov;11(11):2899-937. (PMID: 19622015)
Toxicol Appl Pharmacol. 1993 Dec;123(2):248-56. (PMID: 8248932)
Thromb Haemost. 2018 Apr;118(4):745-757. (PMID: 29554697)
Thorax. 2010 Jan;65(1):57-62. (PMID: 19846469)
Arch Surg. 1996 Jul;131(7):756-60. (PMID: 8678778)
Infect Immun. 1997 Aug;65(8):3293-9. (PMID: 9234789)
J Reconstr Microsurg. 1989 Oct;5(4):343-7; discussion 349-50. (PMID: 2810203)
فهرسة مساهمة: Keywords: biofilm; cytokines; host response; hypoxia; inflammation; neutrophils; reactive oxygen species
المشرفين على المادة: 0 (Anti-Bacterial Agents)
تواريخ الأحداث: Date Created: 20220221 Date Completed: 20220406 Latest Revision: 20220406
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8851036
DOI: 10.3389/fcimb.2022.805964
PMID: 35186793
قاعدة البيانات: MEDLINE
الوصف
تدمد:2235-2988
DOI:10.3389/fcimb.2022.805964